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Background and Purpose.  
We investigated the effectiveness of RPL554 a dual phosphodiesterase 3 and 4 enzyme 
inhibitor, on airway smooth muscle relaxation and compared it to that induced by salbutamol, 
ipratropium bromide, glycopyrrolate or their combination on bronchomotor tone induced by 
different spasmogenic agents.  
Experimental Approach.  
Guinea-pig tracheal preparations were suspended under 1 g tension in Krebs Henseleit 
solution maintained at 37
o
C and aerated with 95% O2/5% CO2 and incubated in the presence 
of indomethacin (5 µM). Relaxation induced by cumulative concentrations of muscarinic 
receptor antagonists (ipratropium bromide or glycopyrrolate), beta2-agonists (salbutamol or 
formoterol), a PDE3 inhibitor (cilostamide, cilostazol or siguazodan) or a PDE4 inhibitor 
(roflumilast) was evaluated in comparison with RPL554.  Maximal relaxation was calculated 
(% Emax papaverine) and expressed as mean ± sem.   
Key Results.  
Bronchomotor tone induced by the various spasmogens was reduced by the different 
bronchodilators to varying degrees.  RPL554 (10-300 M) caused near maximum relaxation 
irrespective of the spasmogen examined, whereas the efficacy of the other relaxant agents 
varied according to the contractile stimulus used.  In further studies to evaluate potential 
synergistic interaction between bronchodilators, RPL554 proved superior to salbutamol when 
either was combined with muscarinic receptor antagonists. 
Conclusions and implications.   
RPL554 produces near maximal relaxation of highly contracted respiratory smooth muscle 
and provides additional relaxation compared with that produced by other clinically used 
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bronchodilator drugs.  This suggests that RPL554 has the potential to produce additional 
beneficial bronchodilation over and above that of maximal clinical doses of standard 
bronchodilators in highly constricted airways of patients. 
 
Abbreviations 
CFTR: cystic fibrosis transmembrane receptor (CFTR) 
COPD: chronic obstructive pulmonary disease 
DMSO: dimethylsulphoxide 
LABA: long acting beta agonist 
LAMA: long acting muscarinic antagonist 
MABA: muscarinic antagonist beta agonist 
PDE: phosphodiesterase 
RPL554: ([9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-
3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] 
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These tables list key protein targets and ligands in this article which are hyperlinked to 
corresponding entries in http://www.guidetopharmacology.org, the common portal for data 
from the IUPAR/BPS guide to Pharmacology (Pawson et al., 2014) and are permanently 
archived in the Concise Guide to PHARMACOLOGY 2015/2016 (Alexander et al., 2015). 
 
 
Introduction  
Bronchodilators including beta2-agonists and muscarinic receptor antagonists are used in 
acute and maintenance therapy of respiratory conditions including asthma and COPD 
(Barnes, 2011; Cazzola et al., 2012).  The clinical effectiveness of these bronchodilators may 
be reduced with both increased disease severity and also during exacerbation of disease 
symptoms.  Hence, there is a need to increase the magnitude of bronchodilation to obtain 
greater clinical benefit.  One approach is the administration of long acting beta2-agonists and 
muscarinic receptor antagonists in combination (Tashkin & Ferguson, 2013; Spina, 2014).  
Similarly, the combination of ipratropium bromide with the short acting beta2-agonist, 
salbutamol is often used in the management of acute asthma, although the added benefit of 
the combination over salbutamol alone is questionable (FitzGerald et al., 1997; Garrett et al., 
1997).   
We have previously reported the clinical effectiveness and absence of significant 
adverse clinical effects such as nausea, emesis and cardiovascular liability of RPL554 the 
dual phosphodiesterase (PDE) 3 and 4 inhibitor in patients with asthma and COPD (Franciosi 
et al., 2013).  The increases in FEV1 observed with this drug are likely a consequence of 
relaxation and functional antagonism of airway tone as demonstrated in guinea-pig isolated 
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trachea (Boswell-Smith et al., 2006) and human bronchial airways (Calzetta et al., 2013; 
Calzetta et al., 2015).   
Sustained bronchoconstriction can lead to airway closure which is associated with an 
increase in disease severity, and risk of exacerbation (Gibbons et al., 1996; Lee et al., 2001).  
The use of inhaled bronchodilators during an acute exacerbation of disease can ameliorate the 
effect of increased smooth muscle tone on airway closure, but comparable or additional 
improvement in clinical indices of symptoms can also be achieved with concomitant 
treatment with intravenous theophylline (Ream et al., 2001; Wheeler et al., 2005) or the 
PDE3 selective inhibitor enoximone (Beute, 2014) additional to standard care with 
bronchodilators and glucocorticosteroids.  Phosphodiesterase inhibitors, particularly dual 
acting inhibitors like RPL554, may also have greater functional antagonistic properties than 
standard inhaled bronchodilators that could provide additional benefit, particularly during an 
exacerbation of asthma. 
We have hypothesised that RPL554 may offer additional bronchodilation in severely 
constricted airways and therefore could provide an adjunct to current treatment modalities in 
the clinic.  In this study, we show that RPL554 produced a greater maximal relaxation 
compared with standard bronchodilators administered alone or combined during different 
experimental conditions to increase bronchomotor tone.  In addition RPL554 enhanced the 
relaxant effect caused by the combination of salbutamol and anti-cholinergic agents.  
Furthermore, this airway smooth muscle relaxant profile exhibited by RPL554 appears to be 
unique and not merely the sum of the addition of a selective PDE3 (e.g. cilostamide) and a 
selective PDE4 inhibitor (e.g. roflumilast).   
 
 
This article is protected by copyright. All rights reserved. 
Methodology 
Group Sizes 
Group sizes are specified in the tables and figures and represent the number of animals used.  
Exact group sizes are shown in the tables and figures.  In some instances, group sizes appear 
unequal as variables were taken from different experiments to calculate the overall global 
mean potency and Emax value for a particular drug under the same experimental conditions.  
In one instance (Table 1), potency values for some drugs were calculated from N=3 and 4 and 
served to give a qualitative measure of drug potency and no formal statistical analysis was 
performed. 
 
Randomization 
There was no formal randomization of tracheal tissue to organ baths, but rather the chance 
allocation of tracheal preparations to organ baths on any experimental day. In a similar 
fashion there was no formal randomization of spasmolytic to tissue preparation from the 
same animal in view of the fact that multiple tracheal tissue preparations were obtained from 
the sample animal.  The observational unit was the animal. 
 
Blinding 
It was not possible to blind the operator to each spasmolytic agent applied to each organ bath. 
The concentration ranges varied between spasmolytic agents hence making it impossible to 
blind to treatment.  The variables measured were not of a subjective nature, rendered blinding 
in this case unnecessary.   
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Normalization 
Relaxation data was expressed as the maximum relaxation response to papaverine (100 M) 
which elicited a complete reversal of bronchomotor tone.  Cumulative concentration response 
curves were fitted to a 3 parameter logistic equation for the determination of potency EC50 
and maximum relaxation.  For each spasmolytic agent, an estimate of EC50 and Emax was 
obtained for each animal and then the geometric mean (95% Confidence interval) and mean 
(SD) of these parameter estimates was calculated. It is well established that concentration 
conforms to a lognormal distribution.   
 
Statistical Analysis 
Unless otherwise specified, parameter estimates are presented as mean + SD and the number 
of animals used is indicated in the table figure legends.  Cumulative concentration-response 
curves were fitted to a 3 parameter logistic equation (GraphPad Prism version 5).  Relaxant 
potency is expressed as geometric mean and 95% confidence interval.  For the analysis of 
synergy, the interaction index (alpha) and additive response for each concentration pair was 
calculated following simultaneous solution of the intercept equation and the sigmoidal 
concentration-response relationship for each spasmolytic agent using SAS version 9.3.  A 
single sample t-test was used to determine evidence of synergy by comparing alpha with the 
population mean of unity.  Comparisons between mean values were deemed statistically 
significant when P < 0.05. A Benjamini-Hochberg multiple comparison test was used to 
adjust P values (InvivoStat version 3.1).  We also undertook an additional statistical analysis 
of data presented in Table 1.  The contractile response of each component spasmogen (as a % 
of the total response) was compared between bath (within group), agonist (within group in 
the instance when 3 different contractile agonists were used) and their interaction (bath x 
agonist) to assess regional trachea differences in contractile potency.  The subject (i.e animal) 
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was a blocking factor to control for between animal variability. Data was analyzed using SAS 
version 9.3.    
 
Validity of animal species or model selection 
Tracheal tissue from guinea-pig was used in these studies.  The guinea-pig is a suitable model 
to study the action of spasmolytic agonists.  Bronchodilator drugs including beta2-
adrenoceptor agonists and muscarinic receptor antagonists inhibit contraction in guinea-pig‟s 
and are clinically effective.  We have previously shown that the dual phosphodiesterase 3 and 
4 inhibitor, RPL554, is a functional antagonist in this species and we have gone on to 
demonstrate the clinical effectiveness of this drug in subjects with asthma and COPD, again 
highlighting the utility of this model in the context of understanding the pharmacology of 
respiratory drugs.  Furthermore, like human airways, guinea-pig trachea responds to 
spasmogenic agents including histamine and LTC4, which are spasmogenic agents used in 
this study. 
 
Ethical Statement 
Ethical approval for the work undertaken in this study was granted by local Animal Welfare 
Ethical Review Board, King‟s College London and permissible under a United Kingdom 
Home Office approved project licence (PPL70/7498).  
 
Animals 
Male Dunkin Hartley guinea-pigs (250-300 g, 6 - 8 weeks, Harland UK). 
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Housing and Husbandry 
 
Animals were housed in groups of six within a Home office (United Kingdom) designated 
Biological Services unit with a 12 h night/day light cycle and access to food and water ad 
libitum.  The cages contained soft bedding and environmental enrichment for welfare 
purposes and the animals were allowed to acclimatize to this environment for 5-7 days after 
arrival to the Unit before use.   
 
Tissue preparation 
 
Male Dunkin Hartley guinea-pigs (250-300 g) were humanely killed by cervical dislocation. 
Trachea and lungs were removed immediately and placed in ice-cold Krebs-Henseleit 
solution. The composition of the Krebs-Henseleit solution, which was gassed with 95% 02: 
5% CO2 and maintained at 37
0
C, was (mM): NaCl 118.0, KCI 4.7, KH2PO4 1.2, MgSO4 1.2, 
NaHCO3 25.0, glucose 11 and CaCl2 2.5 in the absence or presence of Indomethacin (5 M).  
 Following careful removal of adherent fat and connective tissue, the trachea was cut 
into rings (approximately 2 mm i.d and between 1-2 mm thickness). Either four or eight 
tracheal rings were taken from each animal depending on the experiment undertaken to one 
or two of our quadruple organ bath set-ups, respectively. In the case when eight preparations 
were used from the same animal, then two different experiments were conducted between the 
set of four tracheal preparations. There is no evidence of regional differences in relaxant or 
contractile potency along the trachea (Preuss et al., 1998). Furthermore, randomizing tissue to 
organ bath would mitigate against any potential influence of regional variation in tissue 
sensitivity along the length of the trachea. The tissue preparations were then placed in water-
jacketed organ baths at 37
o
C containing Krebs- Henseleit solution and connected to FT03C 
 
This article is protected by copyright. All rights reserved. 
transducers. Tracheal preparations were equilibrated, under 1 g resting load for 40 min, 
before commencement of the experiment. Tension was measured using a Powerlab system 
(ADI, version 5 software).  There was no formal randomization of tracheal tissue to organ 
baths and it was therefore a chance allocation of tracheal tissues to organ baths on any 
experimental day. 
 
Experimental Procedures 
 
Contractile responses 
 
After a 30 to 40 min equilibration period, tissues were contracted with 0.1 and 1 M 
carbachol to confirm tissue viability.  Following a washout period of 30-40 min some tissues 
were contracted with increasing concentrations of carbachol in order to obtain an estimate of 
contractile potency (EC50).  After the contractile response had plateaued, tissues were 
subjected once more to another washing routine and left for a further 30-40 min to 
equilibrate. 
 In other experiments, guinea-pig tracheal tissues were contracted with either 
carbachol (10 x EC50), or combinations of spasmogens added sequentially as follows: 
histamine (10 M) and carbachol (10 M) in the absence or presence of leukotriene (LTC)4 
(100 nM), the latter added first to the organ both.  In other experiments, tracheal tissue was 
contracted with a combination of KCl (40 mM) and carbachol (10 M) added sequentially in 
the absence or presence of LTC4 (100 nM) applied first.  
 In experiments conducted with LTC4, tissues were pre-incubated for 45 min with L-
serine borate (40 mM) and L-cysteine (5mM) to prevent leukotriene metabolism.  For 
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experiments conducted with KCL (40 mM), the Krebs-Henseleit solution was modified by 
reducing the NaCl concentration to 83 mM in order to maintain osmolarity.  Tissues were 
incubated in this modified Krebs-Henseleit solution for a period of 30 to 40 min prior to 
administration of spasmogens. 
 
Relaxation studies 
 
Following stabilization of the contractile response to the different spasmogens and their 
combination, cumulative concentration-response curves to various spasmolytic agents were 
superimposed upon this response.  These included beta2-agonists (salbutamol, formoterol); 
muscarinic receptor antagonists (ipratropium bromide, glycopyrrolate), PDE3 inhibitors 
(cilostamide, cilostazol, siguazodan), PDE4 inhibitors (roflumilast) and the dual PDE3/4 
inhibitor, RPL554.  In other experiments, RPL554 was added in a cumulative fashion in 
tissues after cumulative additions of beta2-agonist or muscarinic receptor antagonist to 
provide evidence of additional relaxation.  In further experiments, combinations (ratio) of 
spasmolytic agents were used and included ipratropium bromide and salbutamol (1:5.7), to 
mimic the dose combination used clinically in nebulizers by subjects with asthma 
(McNamara et al., 2012),glycopyrrolate and RPL554 (1:9, 1:24, 1:226), roflumilast and 
cilostamide (1:1), and siguazodan and cilostamide (1:1).  This approach was used in order to 
determine additivity or synergy with such combinations of relaxant agonists.  We also chose 
to administer increasing concentrations of a combination of PDE3 and PDE4 inhibitor in a 
1:1 ratio, rather than in a sequential fashion (i.e. a single concentration of one inhibitor 
followed by increasing cumulative concentrations of another) to avoid confounding due to 
loss of tracheal tension to either inhibitor in a sequence when comparing relaxation responses 
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between combination of PDE inhibitors and RPL554.  Maximum relaxation was achieved 
with papaverine.   
Analysis of Synergy 
 
We took the opportunity of analyzing the data collected for evidence of a synergistic 
interaction between different spasmolytic agents in some of the experiments undertaken with 
different experimental conditions, using a mathematical approach to describe a synergistic 
interaction between RPL554 and glycopyrrolate in human bronchial tissue (Calzetta et al., 
2013).  To determine synergy for any combination of drugs, denoted a and b respectively, 
requires the simultaneous solution of the cumulative response relationship for both drugs i.e. 
f(A) and f(B) and the intercept equation described below:  
 
 
 
 
Where EmA and EmB represent the maximum relaxation response to drug alone; EC50A and 
EC50B represent relaxant potency for either drug alone, and a, and b the concentration of each 
component in a drug combination, respectively.  The intercept equation a/A + b/B = 1, 
defines the zero interaction relationship between dose combinations, where the denominator 
terms refer to the concentration of drug which alone stimulates an equi-effective response to 
the drug combination as defined by the numerator terms.  The simultaneous solution of these 
equations yields the zero interaction (i.e. additive) concentration-response relationship.  The 
observed effector response for each concentration pair is compared with the corresponding 
additive response (observed-additive). Furthermore, solving the intercept equation for each 
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concentration pair results in the calculation of the interaction index (alpha) and values of 
alpha <1  or =1 denote synergy or additivity, respectively.  (Berenbaum, 1989; Lamarre & 
Tallarida, 2008; Tallarida, 2012).   
 
Materials 
 
Ipratropium bromide, salbutamol sulphate, carbachol chloride, histamine chloride, potassium 
chloride, glycopyrrolate and formoterol fumarate, were prepared in Krebs-Henseleit solution. 
CFTRinh172, iberiotoxin, RPL554, roflumilast, cilostazol, and cilostamide were prepared 
using dimethylsulphoxide (DMSO).  The final concentration of DMSO in the organ bath was 
less than 0.5%. Leukotriene C4 (LTC4) stock solution was obtained in methanol/ammonium 
acetate buffer (65:35) (8x10
-3
M). L-cysteine stock solution (1M) was prepared using Krebs-
Henseleit solution. L-serine borate stock solution was prepared using L-serine (1M) and boric 
Acid (1M) dissolved in water and adjusted to pH 7.4 with 10 M NaOH.  Papaverine 
hydrochloride was prepared in distilled water.  Stock concentrations of drug combinations of 
glycopyrrolate and RPL554 (1:9, 1:24 and 1:226); cilostamide and roflumilast (1:1); and 
siguazodan and roflumilast (1:1) were prepared in DMSO and ipratropium bromide and 
salbutamol („Combivent‟ 1:5.7) prepared in Krebs-Henseleit solution. A stock concentration 
(10 mM) consisted of 1.49 mM ipratropium bromide and 8.51 mM salbutamol, and serial 
dilutions were then prepared.  Dilutions of the stock concentration of all drugs and their 
combinations where made in Krebs-Henseleit solution.  Source of drugs were as follows: 
RPL554 ([9,10-Dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-
3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] (Verona pharma plc and 
synthesized by Onyx Scientific, UK); L-Cysteine, L-Serine, carbachol, glycopyrrolate, 
ipratropium bromide, DMSO, histamine, indomethacin and papaverine hydrochloride 
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(Sigma-Aldrich Company Ltd, UK); cilostamide, iberiotoxin (Cayman Chemical, USA); 
roflumilast (Biovision Inc, USA); siguazodan and CFTRinh172 (Tocris Bioscience, UK); 
cilostazol and salbutamol sulphate (LKT laboratories, USA); formoterol fumarate, LTC4 
(Santacruz Biotechnology, Germany). 
Results 
 
RPL554 functional antagonism studies 
 
Four different spasmogenic conditions were employed to increase bronchomotor tone, 
namely, 1) combination of histamine (10 M) and carbachol (10 M); 2) the combination of 
LTC4 (100 nM), histamine (10 M) and carbachol (10 M) (Fig 1); 3) the combination of 
KCL (40 mM) and carbachol (10 M) (Fig2 A,C,E,G); and 4) the combination of LTC4 (100 
nM), KCL (40 mM) and carbachol (10 M) (Fig 2B,D,F,H).  The cumulative tension 
generated for each contractile agonist and the degree of contraction expressed as a percentage 
of the total contractile response for each condition is summarized in Table 1.  There was no 
significant difference in the magnitude of the total contractile response induced by different 
combinations of these contractile agonists (Table 1).  We also compared the contractile 
response (% Emax, Table 1) for each component in the combination to assess for regional 
variation in contractile activity along the trachea.  There was no evidence of a significant 
difference in regional variation in tracheal contractile response to the spasmogens used in this 
study (P > 0.05, Table 1 footnote). 
 In each of these conditions, RPL554, ipratropium bromide, salbutamol and the 
combination of ipratropium bromide and salbutamol (1:5.7; „Combivent‟) caused a 
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concentration dependent relaxation response.  The degree of reversal was dependent upon the 
combination of spasmogens used to induce bronchomotor tone.  RPL554 fully reversed 
tracheal tension irrespective of which spasmogenic condition was used (Table 2, Fig 1-2).  As 
anticipated, there was a reduction in relaxant potency with RPL554 particularly in tissues 
contracted with potassium ions (Fig 2, Table 2), but nonetheless, full reversal of tone was 
always achieved.  Similarly, whilst the relaxant activity of salbutamol, ipratropium bromide 
and their combination was reduced in tissues exposed to KCL (40 mM), yet full relaxation 
was achieved with the further addition of RPL554 (Fig 2, Table 2).  The relaxant potency and 
maximum relaxation response (expressed as a percentage of reversal of papaverine Emax) for 
each spasmolytic agent is summarized in Table 2. 
 The contractile response of tracheal tissue to LTC4, histamine and carbachol was not 
fully reversed by the long acting muscarinic receptor antagonist, glycopyrrolate (EC50; 2.9 
(0.9 – 8.8) nM, n=6; Relaxation % Emax papaverine, mean, SD; 61 + 10 %, Emax), however, 
the addition of RPL554 fully reverse bronchomotor tone (data not shown).   
 
The effect of PDE3 and PDE4 selective inhibitors on bronchomotor tone 
 
We compared the potency of a range of PDE inhibitors in tissue contracted with carbachol 
(10 x EC50).  The PDE3 inhibitor, siguazodan and the PDE4 inhibitor, roflumilast had lower 
relaxant activity at the concentrations tested with the maximum concentrations employed 
being at least 10-100 x greater than predicted from their isolated enzyme inhibitory potency 
(Fig 3A).  As anticipated bronchodilators like salbutamol sulphate and formoterol fumarate 
caused full relaxation, which was also observed with the PDE3 inhibitors, cilostamide and 
cilostazol as well as the dual inhibitor RPL554 (Fig 3, Table 3).  
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 Bronchomotor tone induced by a combination of histamine (10 M) and carbachol 
(10 M) was not fully reversed by the beta2-agonists salbutamol and formoterol or the PDE3 
selective inhibitors, or cilostamide (Fig 3B), yet under these same conditions the dual PDE 
inhibitor, RPL554 were able to cause near maximum relaxation. The PDE4 selective 
inhibitor, roflumilast, had weak relaxant activity under these assay conditions.  Unlike 
RPL554, a combination of cilostamide and roflumilast (1:1) did not fully reverse 
bronchomotor tone under these conditions (Fig 3B).  In additional experiments, cilostazol, a 
structurally related dihydroquinolinone , did not produce full relaxation (EC50, 95% CI: 9173 
(962 – 87440) nM; % Emax papaverine (SD): 64 (17),  N = 5) alone or in 1:1 combination 
with roflumilast (EC50 value was not estimable with confidence; Emax 39 (11), N = 5).   
In tissues contracted with LTC4 (100 nM), histamine (10 M) and carbachol (10 M) 
both cilostamide alone and in a 1:1 combination with roflumilast (1:1) or the structurally 
unrelated PDE3 inhibitor, siguazodan either alone and in combination with roflumilast (1:1) 
also demonstrated lower relaxant activity than RPL554 alone in tissues contracted (Fig 3C,D 
respectively; Table 3).  For completeness, cilostazol either alone (EC50, 95 % CI; 2919 (694 
– 12460) nM; % Emax papaverine, SD; 66 (12), N = 6) or in combination with roflumilast in 
a 1:1 ratio (1890 (77 – 46400) nM, 52 (12), respectively, N = 6) did not completely reverse 
bronchomotor tone under these experimental conditions.   
 
Interaction studies 
 
We were afforded the opportunity of investigating whether the combination of different 
spasmolytic agents produced a synergistic relaxation response under the different contractile 
conditions employed.  The relaxation response to „combivent‟ (ipratropium bromide and 
salbutamol, 1:5.7) was analysed for any synergistic interaction between the two component 
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bronchodilators in tissues contracted with LTC4, histamine and carbachol (Fig 4A, B) and 
LTC4, KCL and carbachol (Fig 4C,D). The data presented in Fig 4A and 4D were re-drawn 
from the data presented in Fig 1. The zero interaction (additive) relationship for each 
concentration of „combivent‟ was calculated as described in the methods (Fig 3B, 3D; blue 
line).  There appears to be evidence of a greater relaxation response with the combination of 
ipratropium bromide and salbutamol as evidence by a leftward and downwards shift of the 
concentration-response curve to this combination compared with the additive response, 
indicative of a synergistic interaction.  The magnitude of this difference between the observed 
response and the additive response was significant at concentrations greater than 30 nM (% 
relaxation, mean (SD); 25.4 (9) *, 22.6 (6.6) *, 25.2 (6.6) * and 23.6 (6.6), respectively, P < 
0.05 unadjusted, *P < 0.05, Benjamini-Hochberg procedure).  The interaction index (alpha) 
was inestimable because the relaxation response for the combination exceeded the maximum 
response to either drug alone.  This synergistic interaction was absent in tissues contracted in 
the presence of KCL (Fig 3D).   
 We also evaluated the effect of a combination of RPL554 and glycopyrrolate under 
different contractile conditions and found evidence of synergy (Table 4), as assessed by alpha 
values less than unity, and greater relaxation response compared with the additive response 
(i.e. zero interaction effect), for selective concentration pairs of different combination ratios 
in tissues contracted and LTC4 (100 nM), histamine (10 M) and carbachol (10 M) (Fig 
5A,C,E) and with histamine (10 M) and carbachol (10 M) (Fig 5B, D, F).  We also 
observed a synergistic interaction between glycopyrrolate and RPL554 in tissues exposed to 
high concentration of potassium ions (Table 4, Fig 6). Thus, irrespective of the contractile 
conditions employed, evidence of synergy between these two bronchodilators was observed. 
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Further studies 
 
We evaluated the effect of selective inhibitors of CFTR and maxi-K calcium activated 
potassium channels on airway smooth muscle relaxation to agents that elevate intracellular 
cyclic AMP in view of the purported role these ion channels in this response.  The relaxant 
potency (data not shown) to salbutamol or RPL554 was not significantly altered by a CFTR 
inhibitor, CFTRinh 172 (10 M) or the calcium-activated potassium channel blocker, 
iberiotoxin (100 nM) (Fig 7).   
Discussion 
 
In this study, RPL554 produced maximal airway smooth muscle relaxation irrespective of the 
conditions used to induce contraction of guinea-pig isolated trachea. In addition RPL554 
enhanced the airway relaxant effects of salbutamol, ipratropium bromide and their 
combination.  If this translates to the clinical setting the data suggests that RPL554 could 
provide additional bronchodilator relief in severely constricted airways in patients who have 
already received standard care.   
 Clinical studies have demonstrated the ineffectiveness of oral or inhaled PDE4 
inhibitors to act as acute bronchodilators at doses which inhibit indices of the inflammatory 
response or disease process (Grootendorst et al., 2003; Engelstaetter et al., 2005; Rabe et al., 
2005; Fabbri et al., 2009; Singh et al., 2010).  In contrast, inhaled or intravenously 
administered PDE3 inhibitors have been demonstrated to cause bronchodilation in subjects 
with asthma (Fujimura et al., 1997; Myou et al., 2003).  Furthermore, RPL554, a dual PDE 3 
and 4 inhibitor produced bronchodilation in asthmatic and COPD patients (Franciosi et al., 
2013).  These clinical studies point to the importance of PDE3 rather than PDE4 as the major 
isoform which controls the levels of intracellular cyclic AMP within airway smooth muscle 
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cells in humans.  However, the expression of PDE3A in endobronchial biopsies was reduced 
by 2 fold in asthmatic subjects compared with healthy controls.  The expression pattern for 
PDE4 in endobronchial biopsies from patients with asthma was not described in this study, 
possibly because the levels were not altered between the groups (Yick et al., 2013).  PDE 
gene expression has been measured in airway smooth muscle cells maintained in culture.  
The expression of PDE4D was increased and PDE3A unchanged in cultured airway smooth 
muscle obtained from subjects with asthma compared with healthy control subjects (Trian et 
al., 2011; Lin et al., 2015).   
 The PDE activity profile in homogenates of human airway tissue also confirms the 
presence of PDE3 and PDE4 activity, although differences in expression patterns have been 
reported by different laboratories (de Boer et al., 1992; Cortijo et al., 1993; Torphy et al., 
1993) which might be due to regional differences in the expression pattern of PDEs within 
the respiratory tract, although for PDE3 this seems unlikely in view of the relaxation response 
seen with a PDE3 inhibitor in human airways irrespective of anatomical location (de Boer et 
al., 1992; Torphy et al., 1993).  PDE4 accounted for the majority of total PDE activity found 
in tracheal smooth muscle cells from non-asthmatic subjects (Billington et al., 2008), whilst 
PDE3A and to a significantly lesser extent, PDE4D, was shown to be expressed in airway 
smooth muscle cells from intrapulmonary airways from non-asthmatic subjects (Trian et al., 
2011). Neverthless, the expression of PDE4D was increased in airway smooth muscle cells 
derived from subjects with asthma (Trian et al., 2011).  The inhibition of PDE4, but not 
PDE3, using subtype selective inhibitors (Trian et al., 2011), or siRNA for PDE4D5 
(Billington et al., 2008) augmented cyclic AMP levels in response to beta2-adrenoceptor 
stimulation, possibly suggesting a major role for this splice variant which represents a 
fraction of the total PDE4 pool in human airway smooth muscle cells, in the control of cyclic 
AMP levels following acute stimulation of the beta2-adrenoceptor.   
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 Functional studies confirm clinical observations that in general PDE4 inhibitors 
including rolipram and RP73401 produce modest relaxation of human isolated airways, 
whereas greater relaxant activity is observed with PDE3 inhibitors including siguazodan.  
However, these functional responses are dependent on the degree of bronchial or tracheal 
tone and the spasmogenic agent used to contract human airway tissue and therefore is context 
dependent.  In general, as airway contractility is increased the relaxant activity of PDE4 
inhibitors like rolipram is reduced to a greater extent than PDE3 inhibitors like siguazodan 
(Qian et al., 1993; Rabe et al., 1993; Torphy et al., 1993; Naline et al., 1996; Schmidt et al., 
2000).  Furthermore, this context dependence might also explain why in some studies, both 
PDE4 inhibitors (Qian et al., 1993; Naline et al., 1996) and PDE3 inhibitors (Torphy et al., 
1993) augmented the relaxation response to isoprenaline.   
 Similar to these findings in man, tracheal tissue from the guinea-pig also expresses 
both PDE3 and PDE4 isoenzymes and the relaxation response to rolipram and the PDE3 
inhibitor, CL-930, was biphasic and the first phase response was relatively modest (Harris et 
al., 1989).  The relaxation or functional antagonism exerted by PDE3 and PDE4 inhibitors 
was also dependent on the spasmogenic condition employed, but when combined gave a 
greater inhibitory effect than either inhibitor alone (Turner et al., 1994; Underwood et al., 
1994; Bernareggi et al., 1999).  The nature of the biphasic response reported with rolipram is 
unclear, but newer PDE4 inhibitors including roflumilast and cilomilast also produced weak 
or modest reversal of tone in guinea-pig trachea (Bundschuh et al., 2001; Kobayashi et al., 
2012).  The role of PDE4 in airway smooth muscle might be dependent on the spasmogens 
used to contract tissues. For example, contractile responses induced by carbachol, but not 
serotonin, KCL and arginine vasopressin is significantly reduced in PDE4D gene ablated 
mice, or in tracheal preparations from wild type mice treated with rolipram, that was 
specifically dependent upon functional antagonism exerted by endogenously released PGE2 
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(Mehats et al., 2003).  Hence, we also evaluated the relaxant activity of RPL554 in tissues 
contracted with various combinations of spasmogens.   
 In view of the possibility that the contribution of different PDE isoforms for the 
regulation of cyclic AMP levels within airway smooth muscle may vary depending on 
disease status and to the degree of airway tone, it would seem advantageous to inhibit both 
PDE3 and PDE4 in airway smooth muscle and thereby provide more effective 
bronchodilation in most circumstances.  In this study we have demonstrated that the relaxant 
activity of PDE3 and PDE4 selective inhibitors is dependent upon the contractile agonists 
used to induce tracheal airway smooth muscle contraction. The PDE3 selective inhibitors 
cilostamide and cilostazol, produced maximal relaxation in tissues contracted with carbachol 
(10x EC50), whereas cilostamide was less effective in tissues contracted with different 
combinations of spasmogenic agonists.  In all conditions, the PDE4 inhibitor roflumilast only 
produced a modest relaxation.  We did not use concentrations of roflumilast greater than 1 
M in view of the sub nanomolar affinity of this drug for PDE4 (Bundschuh et al., 2001).  
The combination of a PDE3 and PDE4 inhibitor in a 1:1 ratio produce a comparable 
relaxation response compared with either inhibitor alone. However, RPL554 demonstrated 
greater relaxant activity under all spasmogenic conditions used highlighting a novel finding 
in that the relaxation induced by RPL554 is more than merely the combined inhibition of 
separate PDE3 and PDE4 subtype selective inhibitors.  The greater relaxant activity of 
RPL554 might be due its greater inhibitory potency for PDE3 (human platelet PDE3, 0.4 nM) 
(Boswell-Smith et al., 2006) compared with cilostamide (human recombinant PDE3A; 27 
nM) (Sudo et al., 2000); alternatively the combined inhibition of PDE3 and PDE4 by a single 
molecular structure may be more optimal than the combination of two separable isoform 
selective PDE inhibitors.  Alternatively, RPL554 might have a more favourable 
pharmacodynamic profile within airway smooth muscle cells compared with cilostamide, 
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although this seems unlikely in view of the ability of cilostamide to fully reverse 
bronchomotor tone induced by carbachol (10x EC50).  Whether RPL554 has additional 
properties other than inhibition of phosphodiesterase 3 and 4 is currently unknown, although 
we can rule out a role for calcium activated K channels and the cystic fibrosis transmembrane 
receptor (CFTR), given that selective inhibitors of these channels (Jones et al., 1990; Norez 
et al., 2014) did not significantly alter the relaxation response to RPL554.  
We also compared the effect of RPL554 to induce spasmolysis when combined with 
the muscarinic receptor antagonist, ipratropium bromide, the beta2-adrenoceptor agonist, 
salbutamol alone, and in a 1:5.7 combination which has been used to mimic the effects of the 
clinically used “Combivent” preparation in whole animal studies (McNamara et al., 2012).  
As anticipated, the relaxant activity of salbutamol and ipratropium bromide and their 
combination was dependent upon the mixture of different contractile agonists used to induce 
bronchomotor tone.  In tissues which were exposed to KCL (40 mM), it is clear that the 
relaxant activity of these spasmolytics was reduced, but in all cases, additional inhibition of 
bronchomotor tone was achieved with RPL554. If these results are translated to patients, one 
might speculate that dual PDE inhibitors, like RPL554 could offer additional bronchodilator 
activity in severely constricted airways.  This would be consistent, at least in part, with the 
clinically effective bronchodilation observed with RPL554 in subjects with asthma and 
COPD (Franciosi et al., 2013).  In an analogous scenario, the combination of a LABA and a 
LAMA  appears to be superior than either component drug alone in terms of improvement in 
trough FEV1 (Buhl et al., 2015), and the clinical effectiveness of a MABA (Wielders et al., 
2013) in patients with COPD, suggest that single molecule „dual‟ inhibitors may be as 
effective, if not more effective than monocomponent drugs.  We have previously reported 
that RPL554 can elevate intracellular levels of cyclic AMP in human neutrophils (Boswell-
Smith et al., 2006), and other studies have shown that combination of a PDE3 with PDE4 
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inhibitor was more effective than either inhibitor alone in suppressing the generation of 
inositol(1,4,5) triphosphate induced by histamine and carbachol, though more effective 
against the former (Challiss et al., 1998).  Hence, RPL554 offers the possibility of inhibiting 
PDE3 and PDE4 isoenzymes functionally more optimally than selective PDE 3 and 4 
inhibitors used in combination.   
We did not extensively investigate the intracellular mechanism by which RPL554 
gives rise to this additional relaxation response under different spasmogenic conditions, 
although we can rule out an involvement of membrane hyperpolarization via opening of 
calcium activated potassium channels or CFTR.  The reduction in relaxant activity observed 
with beta2-adrenoceptor stimulation in tissues contracted with potassium chloride (Janssen et 
al., 2004) and this study, could be explained by differences in calcium signalling within 
airway smooth muscles by depolarization versus agonists of G-protein coupled receptors 
(Perez & Sanderson, 2005).  In contrast, RPL554 might retain the capacity to elevate 
intracellular levels of cyclic AMP downstream of a PKC dependent impairment of beta2-
adrenoceptor coupling and/or desensitization (Pitcher et al., 1992).  
 Drugs used in combination have the potential to act in an additive or synergistic 
fashion and clinical evidence for synergism has been demonstrated elsewhere for 
combinations of anaesthetics or pain relieving medication (Montes et al., 2000; Manyam et 
al., 2006; Filitz et al., 2008).  The question of whether mechanistically distinct spasmolytics 
can act additively or synergistically has not been fully addressed using mathematical 
approaches that have been developed to investigate this phenomenon (Berenbaum, 1989; 
Lamarre & Tallarida, 2008; Tallarida, 2012).  Previous studies have suggested a synergistic 
interaction between beta2-adrenoceptor agonists and muscarinic receptor antagonists, though 
not analysed rigorously using a mathematical approach of this phenomenon (Rossoni et al., 
2007; McNamara et al., 2012; Smit et al., 2014).  We found some evidence of synergy for 
 
This article is protected by copyright. All rights reserved. 
various combinations of salbutamol and ipratropium bromide, and between RPL554 and 
glycopyrrolate, with the response for some concentration pairs greater than would be 
expected if there was an additive effect (zero interaction).  The later observed consistent with 
a previous study in human bronchial airways (Calzetta et al., 2015).  Interestingly, this effect 
was lost for the combination salbutamol/ipratropium bromide but not RPL554/glycopyrrolate, 
in tissues contracted with KCL (40 mM), again leading to the speculation that RPL554 is 
bypassing impaired beta2-adrenoceptor signalling and in this respect highlights another novel 
finding with the ability of this dual PDE3 and PDE4 inhibitor to maintain synergism under 
conditions in which a synergistic action to beta2-adrenoceptor stimulation is lost.  It has been 
proposed that synergy between the relaxant effects of indacaterol and glycopyrronium is 
mediated in part via the opening of calcium activated K channels (Kume et al., 2014).  Under 
the conditions employed in our study, the high concentration of potassium would render these 
channels inoperable and hence hyperpolarization and closure of voltage operated calcium 
channels would not occur.  This would be expected to functionally antagonise the relaxation 
response to combination ipratropium bromide and salbutamol and hence, could explain this 
loss of synergy.  However, in our studies iberiotoxin did not impair the functional response to 
salbutamol or RPL554, ruling out a role for these ion channels in the relaxation response to 
these cyclic AMP elevating drugs. The change in responsiveness to salbutamol was small 
compared with other reported studies using charybdotoxin or iberiotoxin and may be related 
to differences in the contractile stimulus employed in this study (Jones et al., 1990; Corompt 
et al., 1998). However, the importance of these ion channels in mediating relaxation of 
airway smooth muscle by beta2-adrenoceptor agents is not universally accepted (Huang et 
al., 1993; Corompt et al., 1998; Janssen, 2002; Janssen et al., 2004; Sausbier et al., 2007).  
Moreover, calcium channel blocking drugs do not appear to modify the relaxation to 
isoprenaline in isolated airway preparations (Janssen et al., 2004).   
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 In summary, in circumstances where the spasmolytic activity of a muscarinic 
antagonist or beta2-adrenoceptor agonist alone, or in combination is reduced, we have shown 
that, i) RPL554 provides additional smooth muscle relaxation when administered 
subsequently, ii) there was evidence of specific synergism between that RPL554 and 
glycopyrrolate, iii) that the relaxation produced by RPL554 was greater than that produced by 
the combination of a selective PDE3 and PDE4 inhibitor and iv) that the mechanism of 
airways smooth muscle relaxation is not due to activation of maxi-K channels or CFTR 
activation.  This suggests that RPL554 could not only provide additional benefit to standard 
care in asthma and COPD, but under certain circumstances demonstrate a synergistic 
interaction for smooth muscle relaxation beyond that achieved with salbutamol.   The 
additional anti-inflammatory properties described for RPL554 highlight its potential in the 
treatment of respiratory diseases.   
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Table 1.  Summary of the contractile response to each spasmogen alone and in various 
combinations. 
Contractile agents †Tension (mN) ††Contractile response (% 
Maximum) 
   
Carbachol (10 x EC50)  
   
Carbachol (10x EC50) 28 + 7 (14) 100 
   
Histamine/Carbachol   
Histamine (10 M) 11 + 7 (20)  32 + 34 (20) 
Carbachol (10 M) 35 + 21 (20) 100 
   
LTC4/Histamine/Carbachol   
LTC4 (100 nM) 13 + 6 (29) 47 + 20 (29) 
Histamine (10 M) 21 + 7 (29) 78 + 13 (29) 
Carbachol (10 M) 27 + 9 (29) 100 
  
KCL/Carbachol   
KCL (40 mM)  13 + 8 (10) 42 + 21 (10) 
Carbachol (10 M) 31 + 9 (10) 100 
  
LTC4/KCL/Carbachol   
LTC4 (100 nM)  8 + 8 (13) 26 + 20 (13) 
KCL (40 mM) 19 + 9 (13) 71 + 15 (13) 
Carbachol (10 M) 27 + 8 (13) 100 
   
 
Values expressed as mean + SD with number of animals denoted in parenthesis.   
† Cumulative tension generated by spasmogens.  †† Contractile response to a spasmogen is 
expressed as a percentage of the total contractile response.   We also compared the contractile 
response (% Emax) for each component in the combination to assess for regional variation in 
contractile activity along the trachea.  Contractile response was analyzed by fitting to a model 
defined by fixed factors (organ bath) with the animal as a blocking factor.  There was no 
significant bath effect in the case of Histamine/Carbachol and KCL/Carbachol, or interaction 
between tissue randomized to organ bath and the agonist used in the combination 
LTC4/histamine/carbachol and LTC4/KCL/Carbachol (P > 0.05), highlighting a lack of 
regional variation in response to spasmogens. 
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Table 2.  Summary of spasmolytic potency (EC50) and relaxant activity (relaxation, % 
papaverine Emax) in guinea-pig isolated trachea contracted with different spasmogenic 
agonists. 
 
Contractile 
agents 
Spasmolytic EC50 (95% CI) nM Emax (% 
papaverine) 
N 
 
Histamine/Carbachol  
  
 RPL554 640 (177 – 2310)  100 + 6 5 
 Salbutamol 7 (1.2 – 44) 79 + 25 5 
 Ipratropium bromide 2.8 (0.6 – 15.0) 79 + 15  5 
 „Combivent‟ 16 (6.7 – 36.6) 100 + 5 5 
     
LTC4/histamine/carbachol    
 RPL554 3393 (812-14180) 93 + 9 6 
 Salbutamol 3.2 (1 - 12) 67 + 12* 6 
 Ipratropium bromide 2.5 (1.0 - 6.1) 70+ 19* 6 
 „Combivent‟ 4.4 (1  – 19) 93 + 9 6 
     
KCl/carbachol    
 RPL554 15170 (4290-53660) 94 + 25 10 
 Salbutamol 9.9 (2.9 – 3.4) 43 + 18* 5 
 Ipratropium bromide 6.4 (1.5 – 27.1) 73+ 15* 5 
 „Combivent‟ 11.6 (3.9 – 34.4) 83 + 10* 5 
     
LTC4/KCL/carbachol    
 RPL554 30111 (6406-141600) 97 + 7 5 
 Salbutamol 7.5 (1.8 – 30.7) 42 + 18* 5 
 Ipratropium bromide 7.8 (1.3 – 4.8) 56 + 16* 5 
 „Combivent‟ 41.8 (17.3 – 101) 
 
53 + 8* 5 
 
EC50 and Emax parameter estimates were calculated for each curve by non-linear regression 
and the values represent the global geometric (95% confidence interval) and arithmetic mean 
(SD), respectively from N animals.  * P < 0.05 compared with 100 % maximum relaxation 
(single sample t-test).   
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Table 3.  Summary of spasmolytic potency (EC50) and relaxant activity (relaxation, % 
papaverine Emax) in guinea-pig isolated trachea contracted with different spasmogenic 
agonists. 
 Spasmolytic EC50 (95% CI) nM Emax (% 
papaverine
) 
N 
 
Carbachol (10x EC50)† 
 
  
 RPL554 584 (226 – 1507)  107 + 12 10 
 Salbutamol 24.8 (15.4 – 39.9) 93 + 10 7 
 Formoterol 0.15 (0.01 - 210) 93+ 5  4 
 Cilostazol 1231 (225 - 6724) 98 + 27 4 
 Cilostamide 738 (201 – 2708) 87 + 21 4 
 Siguazodan 79 (9 – 709) 42 + 12 3 
 Roflumilast 22.3 (6.3 – 78.6) 50 + 15* 5 
     
Histamine/ Carbachol   
 RPL554 1617 (303 – 8614)  92 + 11*¶ 17 
 Salbutamol 24 (2 – 250) 51 + 16* 7 
 Formoterol 6.1 (0.3 – 138) 54 + 17* 6 
 Cilostamide 2046 (790 – 5303) 52 + 21* 13 
 Siguazodan 18 (5 – 70) 49 + 14* 5 
 Roflumilast 54 (4 – 650) 41 + 12* 10 
 Cilostamide + Roflumilast 
(1:1) 
27 (0.6 – 1162) 
 
52 + 24* 9 
     
LTC4/histamine/Carbachol    
 RPL554 11080 (4234 – 29010) 99 + 7 11 
 Cilostamide 428 (145 – 1262) 63 + 10* 6 
 Roflumilast 19 (7 – 46) 63 + 16 10 
 Cilostamide + Roflumilast 
(1:1) 
54 (7 – 433) 63 + 12* 6 
 
 Siguazodan 21 (7 – 63)) 45 + 21* 6 
 Siguazodan + Roflumilast (1:1) 119 (29 – 485) 50 + 17* 5 
     
EC50 and Emax parameter estimates were calculated for each curve by non-linear regression 
and the values represent the global geometric (95% confidence interval) and arithmetic mean 
(SD), respectively from N animals.  * P < 0.05 compared with 100 % maximum relaxation 
(single sample t-test).  
¶ 
P < 0.05 compared with other Emax values in this group (Benjamini-
Hochberg procedure for multiple comparison).  † No statistical analysis performed as these 
values serve to show in a qualitative fashion the magnitude of the relaxation response to each 
spasmolytic under this contractile condition. 
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Table 4.  Calculation of interaction index (alpha) and the difference between observed and 
additive relaxation response (O-A) to combination glycopyrronium and RPL554. 
Contractile agents Total 
concentration 
(nM) 
Alpha (mean, SD) O-A (% 
papaverine; 
mean, SD) 
LTC4/histamine/carbachol   
Glycopyrrolate/RPL554    
(1:24) (N=6) 0.1 0.02 (0.02) 6 (5) †† 
 0.3 0.02 (0.01) 15 (14) † 
 1 0.03 (0.02) 23 (16) 
 3 0.04 (0.04) 31 (16) 
 10 0.10 (0.13) 35 (21)  
Histamine/Carbachol   
Glycopyrrolate/RPL554 (1:24) 
(N = 5) 
  
 
 0.1 0.29 (0.36) † 5 (4) † 
 0.3 0.17 (0.13) 13 (7) †† 
 1 0.30 (0.13) 15 (6) 
 3 0.41 (0.08) 18 (4) 
Glycopyrrolate/RPL554 
(1:226) (N = 5) 
  
 
 0.1 0.11 (0.21) 7 (5)  
 0.3 0.07 (0.11) 12(8)  
 1 0.08 (0.10) 20 (10)  
 3 0.11 (0.07) 27 (13)  
 10 0.19 (0.10) 34 (18) 
 30 0.30 (0.15) 34 (17) 
 100 0.48 (0.28)  22 (14) 
 300 0.61 (0.34) 11 (7) 
LTC4/KCL/carbachol   
 
Glycopyrrolate/RPL554 (1:24) 
(N = 6) 
  
 
 1 0.1 (0.2) 11 (6) 
 3 0.04 (0.03) 14 (4) 
 10 0.11 (0.09) 13 (4) 
 30 0.51 (0.21) 17 (14) 
 100 0.60 (0.37) 18 (18) † 
 300 0.47 (0.30) 24 (17) 
 1000 0.49 (0.30) 22 (15) 
 3000 0.42 (0.14) 24 (8) 
Interaction index (alpha) values less than unity are suggestive of a synergistic interaction (all 
alpha values.  Delta (% O-A) represents the difference between the combined (observed: O) 
and the additive (A) response for each concentration pair.  In both cases all values presented 
in this table were statistically different (alpha vs unity; %O-A vs zero) with P values adjusted 
using Benjamini-Hochberg procedure.  Unlesss otherwise specified P < 0.05 following 
adjustment (P > 0.05 prior† and following ††adjustment).   
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Figure 1.  RPL554 provides additional relaxation in combination with various 
spasmolytics.  Concentration-relaxation response curve to (A) RPL554 (open circles), (B) 
salbutamol, (C) ipratropium bromide and (D) „Combivent (closed circles) in tissues 
contracted with LTC4 (100 nM), histamine (10 M) and carbachol (10 M).  Additional 
relaxation response to RPL554 was also detected in tissues fully relaxed to the conventional 
bronchodilators.  Data expressed as mean + SEM, in tracheal tissue from N = 6 animals. 
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Figure 2.  RPL554 provides additional relaxation in combination with various 
spasmolytics. Concentration-relaxation response curve to (A, B) RPL554 (open circles), 
(C,D) salbutamol, (E, F) ipratropium bromide and (G, H) „Combivent‟ (closed circles) in 
tissues contracted with (A,C,E,G) KCL (40 mM) and carbachol (10 M) or LTC4 (100 nM), 
KCL (40 mM) and carbachol (10 M) (B,D,F,H).  Additional relaxation response to RPL554 
was also detected in tissues fully relaxed to the conventional bronchodilators.  Data expressed 
as mean + SEM, in tracheal tissue. Refer to Table 2 for N number.  Data presented in lefthand 
and righthand panels of this figure was derived from different cohorts of animals. 
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Figure 3.  A comparison of spasmolytic activity to various PDE inhibitors in guinea-pig 
isolated trachea.  Concentration-relaxation response curve to RPL554, PDE3 selective 
inhibitors (cilostazol, cilostamide and siguazodan), PDE4 selective inhibitor (roflumilast) and 
beta2-agonists (formoterol and salbutamol) in tissues contracted with (A) carbachol (10 x 
EC50); (B) histamine (10 M) and carbachol (10 M) and (C, D) LTC4 (100 nM), histamine 
(10 M) and carbachol (10 M).  Data expressed as mean + SEM, in tracheal tissue. Refer to 
Table 3 for N number.  Data presented in each panel of this figure was derived from different 
cohorts of animals. 
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Figure 4.   Synergistic interaction between salbutamol and ipratropium bromide is 
inhibited by potassium chloride.  Concentration-relaxation response curve to salbutamol, 
ipratropium bromide and „Combivent‟ in tissues contracted with (A) LTC4 (100 nM), 
histamine (10 M) and carbachol (10 M) and (B) the corresponding comparison of the 
concentration-response curve to the observed response to „combivent‟ and the zero 
interaction relationship (additive).  Data expressed as mean + SEM, in tracheal tissue. Refer 
to Table 2 for N number.  Concentration-relaxation response curve to (C) salbutamol, 
ipratropium bromide and „Combivent‟ in tissues contracted with LTC4 (100 nM), KCL (40 
mM) and carbachol (10 M) and (D) comparison of the concentration-response curve to the 
observed response to „combivent‟ and the zero interaction relationship (additive).  Data 
expressed as mean + SEM, in tracheal tissue. Refer to Table 2 for N number.  Data 
represented in the upper and lower panels of this figure was obtained from different cohorts 
of animals.  
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Figure 5.  Synergistic interaction between RPL554 and glycopyrrolate under various 
contractile conditions, (A) Concentration-relaxation response curve to glycopyrrolate, 
RPL554 alone or in combination (1:9, 1:24) in tissues contracted with LTC4 (100 nM), 
histamine (10 M) and carbachol (10 M).  Data expressed as mean + SEM, in tracheal 
tissue from N = 5-6  animals. Comparison of the relaxation concentration-response curve for 
different combination ratios glycopyrrolate and RPL554 (C, 1:9 respectively and E, 1:24 
respectively) and the zero interaction relationship (additive) for each concentration pair.  
Concentration-relaxation response curve to glycopyrrolate, RPL554 alone or in combination 
(1:24, 1:226) in tissues contracted with (B) histamine (10 M) and carbachol (10 M).  Data 
expressed as mean + SEM, in tracheal tissue from N = 5-7  animals.  Comparison of the 
concentration-response curve to the observed response to the different combination ratios of 
glycopyrrolate and RPL554 (D, 1:249 respectively and E, 1:226 respectively) and the zero 
interaction relationship (additive) for each concentration.  Data represented in the left and 
right panels of this figure was obtained from different cohorts of animals.  There was 
evidence for a synergistic interaction between glycopyrrolate and RPL554 (see Table 4) as 
reflected by a significant interaction index (alpha) and difference between the observed and 
additive relaxation response (% mean (SD) difference).   
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Figure 6.   Synergistic interaction between RPL554 and glycopyrrolate is not altered in 
the presence of potassium chloride.   Concentration-relaxation response curve to 
glycopyrrolate, RPL554 alone or in combination (1:24) in tissues contracted with LTC4 (100 
nM), KCL (40 mM) and carbachol (10 M).  Data expressed as mean + SEM, in tracheal 
tissue from N = 6 animals. For the analysis of synergistic interaction, the additive (zero 
interaction) concentration response curse (additive, blue curve) was calculated for each 
concentration pair.   There was evidence for a synergistic interaction between glycopyrrolate 
and RPL554 (see Table 4) as reflected by a significant interaction index (alpha) and 
difference between the observed and additive relaxation response (% mean (SD) difference).   
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Figure 7.  Relaxation response to RPL554 is not mediated by calcium activated 
potassium channels or CFTR.  Concentration-relaxation response curve to salbutamol (A, 
C) or RPL554 (B, D) in the absence or presence of the calcium activated potassium channel 
blocker, iberiotoxin (A, B) or the cystic fibrosis transmembrane conductance regulator 
(CFTR) channel blocker, CFTRinh172 (C, D).  Data expressed as mean + SEM, in tracheal 
tissue from N = 6 and 5 animals per inhibitor group, respectively.  
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2. TABLES OF LINKS - TARGETS 
 
A quick guide to completing the Tables of Links can be found HERE. (Please view as a slideshow to see the full animation), and a video can be 
found here. 
 
Copy/Paste information into this table as shown in the example in grey shading below 
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Nomenclature Target Id (insert after the 
standard URL below, no spaces) 
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This table lists protein targets and ligands which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common 
portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and the Concise Guide to PHARMACOLOGY 
2013/14 (Alexander et al., 2013a, Alexander et al., 2013b). 
 
This article is protected by copyright. All rights reserved. 
3. TABLES OF LINKS - LIGANDS  
 
A quick guide to completing the Tables of Links can be found HERE. (Please view as a slideshow to see the full animation), and a video can be 
found here. 
Copy/Paste information into this table as shown in the example in grey shading below 
 
LIGANDS    
Ligand name Ligand Id (insert after the standard URL 
below, no spaces) 
INN only IUPAC Name 
cilostamide http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=5167 
cilostamide N-cyclohexyl-N-methyl-4-[(2-oxo-1,2-
dihydroquinolin-6-yl)oxy]butanamide 
cilostazol http://www.guidetopharmacology.org/GRAC/Li
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cilostazol 6-[4-(1-cyclohexyl-1H-1,2,3,4-tetrazol-5-
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rolfumilast 3-(CYCLOPROPYLMETHOXY)-N-(3,5-
DICHLOROPYRIDIN-4-YL)-4-
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formoterol http://www.guidetopharmacology.org/GRAC/Li
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methoxyphenyl)propan-2-
ylamino]ethyl]phenyl]formamide 
ipratropium 
bromide 
http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=325 
ipratropium bromide (8-methyl-8-propan-2-yl-8-
azoniabicyclo[3.2.1]octan-3-yl) 3-hydroxy-2-
phenylpropanoate 
glycopyrrolate http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=7459 
glycopyrrolate (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-
cyclopentyl-2-hydroxy-2-phenylacetate 
salbutamol http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=558 
 
salbutamol 4-[2-(tert-butylamino)-1-hydroxyethyl]-2-
(hydroxymethyl)phenol 
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 Iberiotoxin http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?tab=structure&ligandId=4
218 
iberiotoxin pGlu-Phe-Thr-Asp-Val-Asp-Cys-Ser-Val-Ser-
Lys-Glu-Cys-Trp-Ser-Val-Cys-Lys-Asp-Leu-
Phe-Gly-Val-Asp-Arg-Gly-Lys-Cys-Met-Gly-
Lys-Lys-Cys-Arg-Cys-Tyr-Gln 
histamine http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=1204 
histamine 2-(3H-imidazol-4-yl)ethanamine 
carbachol http://www.guidetopharmacology.org/GRAC
/LigandDisplayForward?ligandId=298 
carbachol 2-carbamoyloxyethyl-trimethylazanium 
indomethacin http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=1909 
indomethacin 2-[1-(4-chlorobenzoyl)-5-methoxy-2-
methylindol-3-yl]acetic acid 
leukotriene C4 http://www.guidetopharmacology.org/GRAC/Li
gandDisplayForward?ligandId=3354 
LTC4 (5S,6R,7E,9E,11Z,14Z)-6-[(2R)-2-[[(4S)-4-
amino-5-hydroxy-5-oxopentanoyl]amino]-3-
(carboxymethylamino)-3-oxopropyl]sulfanyl-5-
hydroxyicosa-7,9,11,14-tetraenoic acid 
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portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and the Concise Guide to PHARMACOLOGY 
2013/14 (Alexander et al., 2013a, Alexander et al., 2013b). 
